ROCHESTER, N.Y., July 15, 2019 /PRNewswire/ -- DuPont today
announced the opening of a new state-of-the-art probiotics
fermentation unit at its Rochester, New
York, facility. Construction of the unit was completed in
March as part of an overall $100MM investment to expand probiotics
capacity. The facility is now producing high-quality probiotics for
the dietary supplement and food and beverage industries, which have
the potential to provide health benefits to consumers of all
ages.
"The investment in our Rochester probiotics operation furthers our
strategy to provide health and nutrition science solutions to this
growing market," said DuPont CEO Marc
Doyle. "With the completion of this facility, we have the
largest fermenter in the world dedicated to probiotics production,
which enhances our ability to provide customers and consumers with
high quality, clinically-documented strains that will positively
impact people's health now and in the future."
The state-of-the-art facility incorporates several new
production innovations, including:
- The world's largest fermenter for probiotics production and its
downstream processing.
- A built-in, fully automated system of sensors and monitors that
helps maintain optimal growing conditions, removing the need to
take traditional manual samples.
- Pressurized air technology to mix fermenting solutions,
replacing traditional pumps and mixing blades that can damage
bacteria.
- New bacteria freezing technology for safe storage of the
probiotics that significantly increases efficiency.
In addition to the company's capital investment, construction of
the fermentation unit was supported by an Upstate Revitalization
Initiative Grant provided by Empire State Development.
Empire State Development President, CEO & Commissioner
Howard Zemsky said, "Supporting the
growth of innovative companies like DuPont, with its new probiotics
fermentation unit at Eastman Business Park, reinforces the strength
of the region's agriculture and food ecosystem and reflects our
strategic focus on recruiting and retaining food production
businesses that drive economic development in the Finger
Lakes."
"We deeply appreciate the support from the state of New York as we launch this industry leading
endeavor," said Matthias Heinzel,
President of DuPont Nutrition & Biosciences. "We're proud to be
part of the Rochester community
and to expand our footprint at the Eastman Business Park. This
investment represents our deep commitment to driving innovation
through probiotic research and manufacturing."
DuPont develops and produces a wide range of
clinically-documented probiotic strains for products sold globally.
In the United States alone, more
than 16 million U.S. households are purchasing probiotics, which
deliver a variety of functional health benefits – from digestive
and immune health to promising advancements in weight management
and even cognitive health. Specifically, HOWARU® Shape – which is
part of the DuPont™ Danisco® portfolio – most recently won
"Ingredient of the Year for Weight Management" at the
NutraIngredients Asia Awards.
About DuPont Nutrition & Biosciences
DuPont Nutrition & Biosciences applies expert science to
advance market-driven, healthy and sustainable solutions for the
food, beverage, dietary supplement and pharmaceutical industries.
We also use cutting-edge biotechnology across a range of markets to
advance bio-based solutions to meet the needs of a growing
population, while protecting our environment for future
generations. We are innovative solvers who help our customers turn
challenges into high-value business opportunities. For more
information: www.dupontnutritionandhealth.com or
www.biosciences.dupont.com.
About DuPont
DuPont (NYSE: DD) is a global innovation leader with
technology-based materials, ingredients and solutions that help
transform industries and everyday life. Our employees apply diverse
science and expertise to help customers advance their best ideas
and deliver essential innovations in key markets including
electronics, transportation, construction, water, health and
wellness, food and worker safety. More information can be found at
www.dupont.com.
Cautionary Statement Regarding Forward Looking
Statements
This communication contains "forward-looking statements"
within the meaning of the federal securities laws, including
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. In this
context, forward-looking statements often address expected future
business and financial performance and financial condition, and
often contain words such as "expect," "anticipate," "intend,"
"plan," "believe," "seek," "see," "will," "would," "target," and
similar expressions and variations or negatives of these
words.
On April 1, 2019, the company
completed the separation of its materials science business into a
separate and independent public company by way of a pro rata
dividend-in-kind of all the then outstanding stock of Dow
Inc. (the "Dow Distribution"). The company completed the
separation of its agriculture business into a separate and
independent public company on June 1,
2019, by way of a pro rata dividend-in-kind of all the then
outstanding stock of Corteva, Inc. (the "Corteva
Distribution").
Forward-looking statements address matters that are, to
varying degrees, uncertain and subject to risks,
uncertainties and assumptions, many of which that are beyond
DowDuPont's control, that could cause actual results to differ
materially from those expressed in any forward-looking statements.
Forward-looking statements are not guarantees of future results.
Some of the important factors that could cause DuPont's actual
results to differ materially from those projected in any such
forward-looking statements include, but are not limited to: (i)
ability and costs to achieve all the expected benefits from the Dow
Distribution and the Corteva Distribution (together, the
"Distributions"); (ii) constraints on DuPont's ability to transfer
certain assets and businesses to third parties without taking
certain actions or meeting certain conditions under an agreement
entered in connection with the Corteva Distribution; (iii)
restrictions under intellectual property cross license agreements
entered into in connection with the Distributions; (iv) non-compete
restrictions under the Separation Agreement entered into in
connection with the Distributions; (v) the incurrence of
significant costs in connection with the Distributions, including
costs to service debt incurred by the company to establish the
relative credit profiles of Corteva, Dow and DuPont and
increased costs related to supply, service and other
arrangements that, prior to the Dow Distribution, were between
entities under the common control of DuPont; (vi) risks related to
indemnification obligations of Historical DuPont contingent
liabilities in connection with the Corteva distribution (vii)
potential liability arising from fraudulent conveyance and similar
laws in connection with the Distributions; (viii) disruptions or
business uncertainty, including from the Distributions, could
adversely impact DowDuPont's business or financial
performance and its ability to retain and hire key personnel; (ix)
uncertainty as to the long-term value of DuPont common stock; (x)
potential inability or reduced access to the capital markets
or increased cost of borrowings, including as a result of a credit
rating downgrade; (xi) uncertainties related to share buybacks
including board approval and costs, time and ability to
complete; and (xii) risks to DuPont's business, operations
and results of operations from: the availability of and
fluctuations in the cost of feedstocks and energy; balance of
supply and demand and the impact of balance on prices; failure to
develop and market new products and optimally manage product life
cycles; ability, cost and impact on business operations, including
the supply chain, of responding to changes in market acceptance,
rules, regulations and policies and failure to respond to such
changes; outcome of significant litigation, environmental matters
and other commitments and contingencies; failure to appropriately
manage process safety and product stewardship issues; global
economic and capital market conditions, including the continued
availability of capital and financing, as well as inflation,
interest and currency exchange rates; changes in political
conditions, including trade disputes and retaliatory actions;
business or supply disruptions; security threats, such as acts of
sabotage, terrorism or war, natural disasters and weather events
and patterns which could result in a significant operational event
for DuPont, adversely impact demand or production; ability to
discover, develop and protect new technologies and to protect and
enforce DuPont's intellectual property rights; failure to
effectively manage acquisitions, divestitures, alliances, joint
ventures and other portfolio changes; unpredictability and severity
of catastrophic events, including, but not limited to, acts of
terrorism or outbreak of war or hostilities, as well as
management's response to any of the aforementioned factors. These
risks are and will be more fully discussed in DuPont's current,
quarterly and annual reports and other filings made with the U.S.
Securities and Exchange Commission, in each case, as may be amended
from time to time in future filings with the SEC. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Consequences of material differences in results as
compared with those anticipated in the forward-looking statements
could include, among other things, business disruption, operational
problems, financial loss, legal liability to third parties and
similar risks, any of which could have a material adverse effect on
DuPont's consolidated financial condition, results of operations,
credit rating or liquidity. You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. DuPont assumes no obligation to publicly provide
revisions or updates to any forward-looking statements whether as a
result of new information, future developments or otherwise, should
circumstances change, except as otherwise required by securities
and other applicable laws. A detailed discussion of some of the
significant risks and uncertainties which may cause results and
events to differ materially from such forward-looking statements is
included in the section titled "Risk Factors" (Part I, Item 1A) of
DuPont's 2018 Annual Report on Form 10-K as modified by DuPont's
2019 quarterly reports on Form 10-Q and current reports on Form
8-K.
DuPont™, the DuPont Oval Logo, and all trademarks and service
marks denoted with ™, ℠ or ® are owned by affiliates of DuPont
de Nemours, Inc. unless otherwise noted.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dupont-opens-world-class-probiotics-fermentation-unit-300884518.html
SOURCE DuPont